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Background and purpose: Both stereotactic radiotherapy (SRT) and immune- or targeted therapy play an
increasingly important role in personalized treatment of metastatic disease. Concurrent application of
both therapies is rapidly expanding in daily clinical practice. In this systematic review we summarize
severe toxicity observed after concurrent treatment.
Material and methods: PubMed and EMBASE databases were searched for English literature published up
to April 2016 using keywords ‘‘radiosurgery”, ‘‘local ablative therapy”, ‘‘gamma knife” and ‘‘stereotactic”,
combined with ‘‘bevacizumab”, ‘‘cetuximab”, ‘‘crizotinib”, ‘‘erlotinib”, ‘‘gefitinib”, ‘‘ipilimumab”, ‘‘lapa-
tinib”, ‘‘sorafenib”, ‘‘sunitinib”, ‘‘trastuzumab”, ‘‘vemurafenib”, ‘‘PLX4032”, ‘‘panitumumab”, ‘‘nivolumab”,
‘‘pembrolizumab”, ‘‘alectinib”, ‘‘ceritinib”, ‘‘dabrafenib”, ‘‘trametinib”, ‘‘BRAF”, ‘‘TKI”, ‘‘MEK”, ‘‘PD1”,
‘‘EGFR”, ‘‘CTLA-4” or ‘‘ALK”. Studies performing SRT during or within 30 days of targeted/immunotherapy,
reporting severe (PGrade 3) toxicity were included.
Results: Concurrent treatment is mostly well tolerated in cranial SRT, but high rates of severe toxicity
were observed for the combination with BRAF-inhibitors. The relatively scarce literature on extra-
cranial SRT shows a potential risk of increased toxicity when SRT is combined with EGFR-targeting tyr-
osine kinase inhibitors and bevacizumab, which was not observed for cranial SRT.
Conclusions: This review gives a best-possible overview of current knowledge and its limitations and
underlines the need for a timely generation of stronger evidence in this rapidly expanding field.
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The management of cancer patients with locally recurrent or
(oligo)metastatic disease has changed fundamentally since the
introduction of immunotherapy and personalized targeted ther-
apy. In parallel, stereotactic radiotherapy (SRT) has become
broadly available and is increasingly used in the same cancer
patient population. An improved understanding of the biological
behaviour of metastatic disease, longer survival and the availability
of these new treatment options has warranted a reconsideration of
previous dogmas related to the combination of targeted systemic
and local therapies, up to a point where a combination of both is
now recommended in multidisciplinary international practice
guidelines (NCCN, IASLC) [1,2].
SRT differs substantially from conventionally fractionated
radiotherapy, which traditionally has been used in the metastatic
setting: high radiation doses aim at long term local tumour control
rather than short-term palliation [3]. Interactions between conven-
tionally fractionated radiotherapy and targeted agents are reason-
ably well understood and toxicity data are available in the
literature [4]. However, it is uncertain whether these observations
can be extrapolated to SRT, which differs from conventionally frac-
tionated radiotherapy in a physics, biological and technological
perspective. With SRT, high radiation doses have been shown to
cause direct vascular damage and endothelial apoptosis, thereby
increasing tumour cell-destruction [5,6]. Furthermore, SRT might
stimulate the antitumour immune response, that will act both
http://dx.doi.org/10.1016/j.ctrv.2016.11.013
0305-7372/ 2016 The Author(s). Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
⇑ Corresponding author. Fax: +41 44 255 4547.
E-mail address: Stephanie.kroeze@usz.ch (S.G.C. Kroeze).
Cancer Treatment Reviews 53 (2017) 25–37
Contents lists available at ScienceDirect
Cancer Treatment Reviews
journal homepage: www.elsevierheal th.com/ journals /c t rv
locally within the irradiated volume as well as systemically and
could enhance the effectivity of immunotherapies [7–9]. Although
the sparing of healthy tissue from higher irradiation doses makes
radiotherapy less toxic, the spread of low irradiation doses over
large volumes of parallel organs such as the lung may potentially
increase toxicity [10]. Consequently, differences in radiobiology
[11] might result in unexpected interactions and toxicity profiles
within a multimodality treatment strategy. This systematic review
aimed to summarize all currently available published data about
toxicity of concurrent SRT and targeted therapy or
immunotherapy.
Material and methods
We performed a systematic literature search according to the
‘PRISMA’ guideline [12]. PubMed and EMBASE databases were
searched with the MeSH and free text search terms ‘‘radiosurgery”,
‘‘local ablative therapy”, ‘‘gamma knife” and ‘‘stereotactic”, com-
bined with ‘‘bevacizumab”, ‘‘cetuximab”, ‘‘crizotinib”, ‘‘erlotinib”,
‘‘gefitinib”, ‘‘ipilimumab”, ‘‘lapatinib”, ‘‘sorafenib”, ‘‘sunitinib”,
‘‘trastuzumab”, ‘‘vemurafenib”, ‘‘PLX4032” ‘‘panitumumab”,
‘‘nivolumab”, ‘‘pembrolizumab”, ‘‘alectinib”, ‘‘ceritinib”,
‘‘dabrafenib”, ‘‘trametinib”, ‘‘BRAF”, ‘‘TKI”, ‘‘MEK”, ‘‘PD1” ‘‘EGFR”,
‘‘CTLA-4” or ‘‘ALK”. The targeted agents were selected based on
approval for use in solid tumour types that are also regularly trea-
ted with SRT. The search for publications was limited to the English
language and original articles. No limitation was placed on publica-
tion year; studies published up to the end of April 2016 were
reviewed. Only original articles were included. Conference
abstracts, reviews, book chapters, commentaries, editorials and
articles that were not peer-reviewed were excluded. References
from included studies were reviewed and cross-referenced to
ensure completeness.
SRT was defined by fraction dosesP5 Gy and 68 fractions. Tar-
geted therapy had to be given concurrently to SRT, or initiated
within 30 days before or after radiation. Studies treating benign
diseases or patients younger than 18 years old, not (clearly)
describing toxicity or timing of SRT in relation to targeted therapy
were excluded. Toxicity had to be either graded according to the
National Cancer Institute Common Terminology Criteria for
Adverse Events (CTCAE), or properly described. When toxicity
was not graded according to the CTCAE, the authors rated the tox-
icity accordingly.
Two authors (S.K. and C.F.) performed the study selection inde-
pendently. Disagreements were resolved by consensus with the
senior author (M.G.). Titles and abstracts were used to screen for
initial study inclusion. Full-text review was used when the abstract
provided insufficient data to determine whether the study met
inclusion or exclusion criteria. Two authors (S.K. and C.F.) per-
formed all data abstraction. The following data was extracted: year
of publication of the study, study type, patient and tumour charac-
teristics, radiation dose and fractionation, type and dosage of tar-
geted therapy used, timing of the concurrent targeted therapy
and radiotherapy and toxicity. Only Grade 3 or higher toxicities
were included for analysis.
Results
Included studies and overview
Our literature search identified 1038 references (Fig. 1). After
adjusting for duplicates 843 unique citations remained and follow-
ing title and abstract review, 102 relevant articles underwent full
text review. Of these, 53 did not meet the inclusion criteria, result-
ing in 49 remaining articles that were included into this systematic
review (Tables 1a and b). These included 13 (321 patients)
prospective studies, 27 (653 patients) retrospective studies and 9
(16 patients) case reports. No articles reporting toxicity of SRT with
concurrent lapatinib, panitumumab, alectinib, ceritinib and pem-
brolizumab were found. The number of patients per study ranged
from 1 to 106 patients, with a median of 15 patients (Table 2).
Whereas SRT for intra-cranial lesions was reported in 34 studies,
SRT for extra-cranial sites was only reported in 19 studies (Fig. 2).
For targeted agents combined with cranial SRT (n = 644), grade
3, grade 4 and grade 5 toxicity was observed in 74 (11%), 14 (2%)
and 1 patient(s), respectively (Fig. 3a). Less than half (5.4% Gr3;
0.6% Gr4; 0% Gr5) of these adverse events were considered directly
related to the SRT (Table 2). For extra-cranial SRT (n = 524), severe
toxicity was reported as grade 3 in 73 (14%), grade 4 in 8 (2%) and
grade 5 in 3 patients (0.6%) (Fig. 3b). Approximately half of these
toxicities could be related to the SRT or the concurrent therapy
(7.6% Gr3; 0.8% Gr4; 0.6% Gr5) (Table 2). Overall, SRT-induced sev-
ere toxicity was lower for cranial compared to extra-cranial SRT
(6% vs. 9%). The remaining events were attributed to the targeted
therapy alone (Table 2, Fig. 4).
Toxicity of concurrent SRT and antibody therapy
Anti-VEGF (bevacizumab)
SRT was combined with bevacizumab in 4 prospective [13–16],
7 retrospective studies [17–23] and 1 case report [24]. All but one
reported on cranial SRT of (recurrent) glioblastoma (GBM) or brain
metastases (Table 1b). Radiation was performed with a median
dose of 12.5 to 24 Gy in 1 fraction or 20 to 50 Gy in 3–6 fractions.
The median follow-up ranged from 4 to 42 months. In total, 47 sev-
ere toxicity events (PGrade 3) were reported in 206 patients
(Table 2, Fig. 4).
For cranial SRT, grade 3/4 toxicity outside the radiation field
was observed in 16% of patients and consisted mainly of haemato-
logical disorders (Table 2). No grade 5 toxicity was reported. Severe
local toxicity within the irradiated volume was observed in 12 out
of 192 patients (6%) (Table 2b). Of these, 2 were grade 4 (wound-
healing disorder, surgical wound infection). Grade 3 toxicity within
the irradiated volume consisted of radionecrosis (n = 1), headache
(n = 1), worsening of neurological symptoms (n = 1), change in
memory (n = 1), wound dehiscence (n = 1), CNS haemorrhage
(n = 1), dysphasia (n = 1) and seizures (n = 2). Cuneo et al. com-
pared SRT alone to SRT with bevacizumab and found that toxicity
rates did not differ significantly [20]. One study reported a
decreased risk of radionecrosis and cerebral oedema after SRT
combined with bevacizumab [16].
For extra-cranial SRT, only the study of Barney et al. reported 14
patients treated with bevacizumab within one month after abdom-
inal SRT [17]. SRT was performed with a median dose of 50 Gy in 1
to 5 fractions. One grade 4 gastric perforation was observed in a
patient that started bevacizumab two weeks after SRT, and one
grade 3 gastric ulcer in a patient that received concurrent therapy
[25].
In summary, the additional risk of concurrent cranial SRT and
bevacizumab appears to be small or non-existing in terms of neu-
rological toxicity, and could possibly even be protective to the
development of radionecrosis. Data on the combination of beva-
cizumab and SRT at extra-cranial locations is scarce but indicates
that the use of concurrent abdominal SRT and bevacizumab should
be practised with caution.
Anti-EGF-R (cetuximab)
Three prospective [26–28] and 3 retrospective trials [29–31]
were identified (n = 224 patients, Table 2). All evaluated recurrent
head-and-neck cancer (HNC) and initiated cetuximab 1 week
before SRT. The median SRT dose was 36 or 40 Gy in 5 or 6 frac-
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tions. Median follow-up ranged from 6 to 25.6 months. Overall, 32
severe toxicities were observed in 172 patients (19%), of which 31
were grade 3 and 1 grade 5 (Table 2, Fig. 1a). The most commonly
observed toxicity within the irradiated volume was dermatitis
(n = 6), mucositis (n = 7) or dysphagia (n = 8). The single grade 5
toxicity represented a patient with severe malnutrition and fatal
bleeding [27]. The retrospective study by Vargo et al. observed a
significant increase in severe acute toxicity of a concurrent therapy
compared to SRT alone (13 vs. 10%, p = 0.008), whereas severe late
toxicity was not significantly more prevalent [28]. A potentially
increased grade 3 toxicity of combined SRT and cetuximab com-
pared to SRT alone was also reported by Comet et al. (3 of 15 vs.
1 of 25 patients); no statistical analysis was performed in this
small number of patients [26].
In summary, cetuximab has been combined with SRT only for
treatment of recurrent HNC in previously irradiated patients. There
appears to be considerable risk of severe acute toxicity, but
hypofractionated reirradiation of the head and neck alone is asso-
ciated with a high risk of acute and late toxicity as well; conse-
quently, it is not clear to which extent concurrent cetuximab
adds to the toxicity.
Anti-Her2 (trastuzumab)
Only one case report has been published [32]. This study
reported on 7 Her2 + breast cancer patients that received stereo-
tactic radiosurgery (SRS) of 22 cerebral metastases, with concur-
rent trastuzumab therapy. Trastuzumab was initiated median
8.5 days after SRT, with a large range of 3 to 449 days. SRS was per-
formed with single fraction doses of 18, 20 or 24 Gy. Acute grade 4
cerebral oedema was observed in 1 patient (14%). No late toxicity
was observed.
In summary, the very limited available data does not indicate
increased toxicity of cranial SRT combined with trastuzumab. Data
on the combination of trastuzumab and extra-cranial SRT is
lacking.
Toxicity of concurrent SRT and immune checkpoint inhibition
Anti-CTLA-4 (ipilimumab)
Six retrospective studies [33–38] and 2 case reports [39,40]
were identified (Table 2). All retrospective analyses examined
SRT concurrent to ipilimumab in melanoma brain metastases.
The median SRT dose ranged from 14 to 60 Gy in 1–5 fractions
and median follow-up ranged between 7.3 and 33.1 months. Sev-
ere toxicities were mainly ipilimumab-induced, and ipilimumab
combined with SRT did not increase toxicity compared to ipili-
mumab alone (Table 2) [36]. Kiess et al. observed 2 grade 3 sei-
zures and 2 grade 3 CNS haemorrhages (13%) that could be
attributed to SRT alone or the concurrent treatment [33] and there
was a trend towards increased CNS toxicity in the concurrent ther-
apy group. In addition, studies of Silk et al., Mathew et al. and Patel
et al. did not find increased toxicity after combined treatment
[34,35,37]. Symptomatic radiation necrosis after the combined
therapy was observed in the study of Patel et al., but not more fre-
quently than after SRT alone [35].
Fig. 1. Search flow diagram.
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Table 1a
Included articles with concurrent SRT and tyrosine kinase inhibitor treatment.
Study Study
year
Study type N
(patients/
lesions)
Dose (Gy)
(median/
fractions)
Targeted drug Start of targeted drug Primary tumor Treated site Treatment
timing
Follow-up
(median
months)
Toxicity
(P3)
Infield
Toxicity
(P3)
Staehler et al.
[44]
2010 Restrospective 106 (106) 20/1 Sorafenib 400 mg p.o/1 d (n = 45);
Sunitinib 50 mg p.o./1 d 4 w in
6 w cycle (n = 61)
Concurrent RCC Brain; Spine Advanced
metastatic
14.7 Y Y
Brade et al.
[45]
2016 Phase 1 trial 16 (16) 33, 51/6 Sorafenib 200 mg/400 mg p.o./1 d Concurrent, start 7 d
before SRT
HCC Liver Primary
treatment
11 Y Y
Straka et al.
[46]
2013 Case report 1 (1) 60/5 Sunitinib, dosage NR 14 m before SRT, paused
during SRT
RCC Adrenal Oligoprogression 8 N N
Ahluwalia
et al. [43]
2015 Phase 2 trial 14 (25) SRS dose
NR
Sunitinib 37.5 mg or 50 mg p.o./
1 d, 4 w in 6 w cycle
Start up to 1 m after SRT Lung cancer
(n=6); Breast
cancer (n=3),
Melanoma (n=2);
Other (n=3)
Brain Oligoprogression 11.7 Y N
Wang et al.
[51]
2014 Prospective 14 (14) 45, 60/3 Gefitinib 250 mg p.o./1 d Concurrent, start 7 d
before SRT
NSCLC Lung Advanced
metastatic
15.5 Y Y
Schwer et al.
[49]
2008 Phase 1 trial 15 (15) range
18–36/3
Gefitinib 250 mg p.o./1 d Concurrent, start 7 d
before SRT
Glioma Brain Local recurrence 7 N N
Kim et al. [48] 2015 Restrospective 18 (31) 23/1 Gefitinib 250 mg p.o./1 d;
Erlotinib 150 mg p.o./1 d
Concurrent NSCLC Brain Advanced
metastatic
31.9 N N
Iyengar et al.
[47]
2014 Phase 2 trial 24 (52) range
19–40/
1–5
Erlotinib 150 mg p.o./1 d Concurrent, start 1–3 w
before SRT
NSCLC Lung; Liver;
Kidney; Bone;
Adrenal;
Mediastinum;
Lymph node
Oligometastatic
disease
11.6 Y Y
Gan et al. [52] 2014 Restrospective 14 (29) range
12–54/
1–3
Crizotinib, dosage NR Concurrent, paused
during SRT
NSCLC extraCNS (lung,
liver, other
locations NR)
Oligoprogression 11.5 N N
Weickhardt
et al. [50]
2012 Retrospective 25 (NR) SRT or
SRS dose
NR
Crizotinib 250 mg p.o./2xd
(n = 15); Erlotinib 150 mg p.o./1d
(n = 10)
Concurrent, paused
during SRT
NSCLC Brain; Lung;
Lymph node;
Bone; Liver;
Adrenal
Oligoprogression 20 N N
Ahmed et al.
[54]
2015 Retrospective 24 (80) 21/1 Vemurafenib 960 mg p.o./2xd Median 5.2 m (0.4–
17.1 m) before SRT,
paused 2–3 days before/
after SRT
Melanoma Brain Oligometastatic
disease
5.1 Y Y
Peuvrel et al.
[60]
2013 Case report 1 (2) 20/1 Vemurafenib 960 mg p.o./2xd 3 months before SRT,
concurrent
Melanoma Brain Oligoprogression NR Y Y
Narayana
et al. [57]
2013 Retrospective 6 (14) 20/1 Vemurafenib 960 mg p.o./2xd Before, concurrent or
after SRT median 8.7 w
(range 2.6–113.6 w)
Melanoma Brain Advanced
metastatic
12.2 N N
Ly et al. [57] 2015 Restrospective 17 (96) 20/1 Vemurafenib 720 mg (n = 4) or
960 mg (n = 3) p.o./2xd (n = 4);
Dabrafenib 150 mg p.o./2xd
(n = 9); unknown BRAF-Inhibitor
(n = 1)
Before or after SRT,
paused during SRT
median 7 days, range
1–20 days
Melanoma Brain Advanced
metastatic
10.5 NR NR
Liebner et al.
[59]
2014 Case report 2 (4) 22, 24,
27/1 or
30/5
Vemurafenib 960 mg p.o./2xd 1–3 m before SRT,
paused during SRT
Melanoma Brain Advanced
metastatic
NR Y Y
Stefan et al.
[61]
2016 Case report 1 (1) 10/1 Vemurafenib 960 mg p.o./2xd Concurrent, 1 m before
SRT
Melanoma Spine Advanced
metastatic
NR N N
Gaudy et al.
[55]
2014 Retrospective 24 (209) 20, 28/1 Vemorafenib (n = 20); Dabrafenib
(n = 4), dosage NR
Concurrent (n = 20)
2.5 t1/2 after SRT (n = 4)
Melanoma Brain Advanced
metastatic
4.7 Y Y
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Two case reports of SRT concurrent with ipilimumab in liver
metastases from NSCLC and melanoma did not observe any signif-
icant toxicity [39,40].
In summary, the available studies are small but suggest that
concurrent cranial SRT with ipilimumab is safe. There is very lim-
ited data on the use ipilimumab concurrent with extra-cranial SRT.
Anti-PD-1/PD-L1 (nivolumab, pembrolizumab)
Our search did not find studies on concurrent pembrolizumab
and SRT. For nivolumab, only 1 case report of SRT for NSCLC brain
metastases and 1 retrospective study of SRT for melanoma brain
metastases was identified [41,42]. The case report by Alomari
et al. observed a grade 4 cerebral oedema in one patient receiving
concurrent therapy [41]. Ahmed et al. reported two events of grade
3 cerebral oedema in 20 patients treated with SRT and nivolumab
for melanoma brain metastases (Table 2) [42].
In summary, the data on combined SRT and nivolumab is insuf-
ficient for conclusions, both for cranial and extra-cranial SRT. Data
about the combination of pembrolizumab with SRT is not available.
Toxicity of concurrent SRT and tyrosine kinase inhibitors (TKIs)
Multi receptor tyrosine kinase inhibitors (sorafenib, sunitinib)
Two studies examined SRT of cerebral metastases from several
tumour types [43,44]. In the retrospective study of Staehler et al.
[44] where 51 patients received concurrent cranial SRT for cerebral
metastases with sorafenib or sunitinib, no radiation necrosis was
observed, but 1 patient developed a fatal cerebral bleeding
3 months after SRT concurrent with sunitinib. The prospective
phase 2 trial of Ahluwalia et al. with concurrent sunitinib and
SRT for cerebral metastases reported 12 severe toxicities in 8 out
of 14 patients (57%), which were all extra-cranial and not likely
caused by the radiation therapy (Table 2) [43].
We found 2 studies examining concurrent extra-cranial SRT
with sorafenib [44,45] and 3 with sunitinib [43,44,46]. These stud-
ies were highly diverse in study type, tumour type and location of
SRT. Three studies examined concurrent therapy with SRT in the
abdomen: Brade et al. evaluated SRT of intrahepatic HCC, Straka
et al. SRT of adrenal metastases in RCC and Staehler et al. SRT of
spinal metastases in RCC [44–46]. Staehler et al. observed grade
3 toxicity in 23% of a total of 106 patients (n = 51 cranial and
n = 55 extra-cranial), which were all attributed to the TKI therapy
and not to concurrent SRT (Table 2) [44]. Brade et al. observed sev-
ere toxicity that was potentially caused by the concurrent SRT of
HCC. [45] Grade 3 toxicity was observed in 9 of 16 patients
(56%); SRT-induced toxicity included liver enzyme changes
(n = 2) and lower GI haemorrhage (n = 1). Two patients developed
grade 4 toxicity (13%), consisting of liver failure and small bowel
obstruction. One patient died after an upper GI haemorrhage. Sor-
afenib had to be discontinued in 4 patients and 13 out of 16
patients required a dose modification. Straka et al. found no toxic-
ity after treatment of one patient with sunitinib combined with
SRT of an adrenal metastases of RCC [46].
In summary, cranial SRT combined with sorafenib of sunitinib
appears to be safe but one grade 5 toxicity has been observed for
sunitinib. For extra-cranial SRT, liver SRT combined with sorafenib
is associated with a high risk of severe toxicity, which has not been
observed for sorafenib and SRT in other extra-cranial locations. No
radiation induced toxicity has been observed after sunitinib and
extra-cranial SRT.
EGF-R-inhibitors (gefitinib, erlotinib, lapatinib)
Five studies (n = 81 patients) examining concurrent gefitinib or
erlotinib and SRT were identified (Table 1a) [16,47–50]. These
studies were diverse in study type and location of SRT, but mainlyTa
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Table 1b
Included articles with concurrent SRT and antibody treatment.
Study Study
year
Study type N
(patients/
lesions)
Median dose
(Gy)/fractions
Targeted therapy Start of targeted therapy Primary tumor Treated
site
Treatment
timing
Follow-
up
(median
months)
Toxicity
(P3)
Infield
Toxicity
(P3)
Cuneo et al.
[20]
2012 Retrospective 42 (42) 15 (12.5–25)/
1–5
Bevacizumab, dosage
NR
Concurrent or after SRT Glioma Brain Local recurrence 7 Y NR
Gutin et al.
[14]
2009 Prospective
pilot study
25 (25) 30/5 Bevacizumab, 10 mg/
kg i.v./2 w
Concurrent Glioma Brain Local recurrence 6.6 Y Y
Wang et al.
[16]
2014 Prospective
pilot study
8 (8) 30/1–5 Bevacizumab, 5 mg/
kg i.v./2 w
Start 3–10 d (median 5 d) after SRT CRC; NSCLC;
Maxillary gland;
Esophagus;
Gastric
Brain Oligometastatic
disease
5 N N
Yomo et al.
[23]
2015 Retrospective 5 (9) 18/1 Bevacizumab, 7.5–
10 mg/kg i.v./3-4 w
Start 1 d after SRT NSCLC, CRC Brain Oligoprogression 4.5 Y N
Minniti et al.
[22]
2015 Retrospective 26 (26) 25/5 Bevacizumab, 10 mg/
kg iv./2 w
Concurrent Glioma Brain Local recurrence 12 Y Y
Omuro et al.
[15]
2014 Phase 2 trial 40 (40) 36/6 Bevacizumab, 10 mg/
kg i.v. and
Temozolamide
75 mg/m2 p.o.
Concurrent Glioma Brain Primary
treatment
42 Y Y
Cabrera et al.
[13]
2013 Prospective
pilot study
15 (15) 24/1, 18/1,
25/5
Bevacizumab, 10 mg/
kg i.v./2 w
Concurrent Glioma Brain Local recurrence 30 Y Y
Clark et al.
[18]
2014 Retrospective 21 (21) 30/5 Bevacizumab, 10 mg/
kg i.v.
Concurrent Glioma Brain Local recurrence 8.5 Y Y
Hasan et al.
[21]
2015 Retrospective 9 (9) 25/3–5 Bevacizumab, dosage
NR
Before or after SRT Glioma Brain Local recurrence 5.3 N N
Conde et al.
[19]
2015 Retrospective 9 (9) 30/5 Bevacizumab, 10 mg/
kg i.v./2 w
Concurrent Glioma Brain Local recurrence 38 NR NR
Cabrera et al.
[24]
2012 Case report 1 (1) 18/1 Bevacizumab, 10 mg/
kg i.v./2 w
Concurrent Glioma Brain Local recurrence 4 N N
Barney et al.
[17]
2013 Retrospective 14 (NR) 50/1–5 Bevacizumab 5 mg or
10 mg/kg/2 w, or
15 mg/kg/3 w
Median 3.3 m, (range 0.0–4 m) after
SRT
HCC; CRC;
Pancreas;
Melanoma; RCC
Lymph
node;
Liver;
Pancreas
Advanced
metastatic
15.4 Y Y
Carlson et al.
[32]
2014 Case report 7 (22) 18/1, 20/1,
24/1
Trastuzumab, dosage
NR
Median 8.5d (range 3–449 d) after
SRT
Her2 + breast
cancer
Brain Local recurrence NR Y Y
Vargo et al.
[28]
2015 Phase 2 trial 48 (48) 40/5 Cetuximab 400 mg/
m2 i.v., after that
250 mg/m2/1 w
Concurrent, start 7 d before SRT SCCHN Head-
and-neck
Local recurrence 18 Y Y
Lartigau et al.
[27]
2013 Phase 2 trial 56 (56) 36/6 Cetuximab 400 mg/
m2 i.v., after that
250 mg/m2/1 w
Concurrent, start 7 d before SRT SCCHN Head-
and-neck
Local recurrence 11.4 Y Y
Vargo et al.
[31]
2014 Retrospective 72 (72) 40/5 Cetuximab 400 mg/
m2 i.v., after that
250 mg/m2/1 w
Concurrent, start 7 d before SRT HNC Head-
and-neck
Local recurrence 6 Y NR
Comet et al.
[26]
2011 Prospective
pilot study
15 (15) 36/5 Cetuximab 400 mg/
m2 i.v., after that
250 mg/m2/1 w
Concurrent, start 7 d before SRT HNC Head-
and-neck
Local recurrence 25.6 Y Y
Heron et al.
[29]
2011 Retrospective 35 (35) 40/5 Cetuximab 400 mg/
m2 i.v., after that
250 mg/m2/1 w
Concurrent, start 7 d before SRT SCCHN Head-
and-neck
Local recurrence 15.9 Y Y
Quan et al.
[30]
2016 Retrospective 18 (18) 40/5 Cetuximab 400 mg/
m2 i.v., after that
250 mg/m2/1 w
Concurrent, start 7 d before SRT SCCHN Head-
and-neck
Local recurrence 25.6 Y Y
Kiess et al.
[33]
2015 Retrospective 15 (NR) 21/1 Ipilimumab 3 mg or
10 mg/kg/3 w
Concurrent Melanoma Brain Advanced
metastatic
22 Y Y
30
S.G
.C.K
roeze
et
al./Cancer
Treatm
ent
R
eview
s
53
(2017)
25–
37
included NSCLC patients. No studies with concurrent lapatinib
were found.
Regarding cranial SRT, Schwer et al. performed a Phase 1 trial in
15 patients for recurrent glioma treated with gefitinib and SRT,
which showed no severe toxicity [49]. Kim et al. retrospectively
analysed SRT combined with gefitinib or erlotinib for NSCLC brain
metastases in 18 patients and observed no severe toxicity [48].
Weickhardt et al. also did not observe severe toxicity in 7 patients
treated with erlotinib or crizotinib and cranial SRT [50].
Regarding extra-cranial SRT, the prospective study of Wang
et al. used SRT to treat a maximum of 3 lung metastases in stage
IV NSCLC patients (n = 14) with concurrent gefitinib [51]. Grade 3
toxicity possibly caused by the concurrent treatment occurred in
4 patients (29%), consisting of stomatitis, esophagitis, and radiation
pneumonitis (n = 3) (Table 2). One patient received a dose reduc-
tion of gefinitib because of toxicity. Iyengar et al. prospectively
treated extra-cranial NSCLC metastases with concurrent erlotinib
and SRT; 29 severe toxicity events were observed in 24 patients,
of which 4 were definitely attributed to SRT. These include one
grade 4 toxicity described as hypoxia that resulted in a grade 5
ARDS/pneumonia in the same patient, and 2 grade 3 toxicity
events, described as vertebral body compression and radiation
pneumonitis. The 12 deaths were described as not related to con-
current therapy [47]. Weickhardt et al. did not observe any severe
toxicity in their retrospective study of SRT and concurrent erlotinib
in 10 patients with NSCLC [50].
In summary, concurrent EGF-R-targeting TKIs and extra-cranial
SRT might be associated with increased toxicity within the irradi-
ated volume in the treatment of abdominal and thoracic metas-
tases; however, no increased toxicity was observed in cranial
SRT. Data about the combination of lapatinib with SRT is not
available.
ALK-Inhibitors (crizotinib, ceritinib, alectinib)
Only 2 retrospective studies, treating a total of 29 patients with
concurrent crizotinib and SRT for oligoprogressive NSCLC in cranial
and extra-cranial metastases, were found (Table 1a). Gan et al. per-
formed SRT with a range of 12 to 54 Gy in 1–3 fractions [52];
Weickhardt et al. did not describe detailed SRT doses. In both stud-
ies, crizotinib was paused during SRT treatment [50]. No severe
toxicity was observed (Table 2).
In summary, available data does not allow for a robust conclu-
sion on safety of combined crizotinib, ceritinib, alectinib and SRT.
BRAF-Inhibitors (vemurafenib, dabrafenib)
Toxicity of SRT combined with BRAF-inhibitors was reported in
10 studies (Table 1b). All studies performed radiosurgery (mean
dose ranging from 18 to 27 Gy) for melanoma brain metastases;
of these, one was a prospective study [53], 6 were small retrospec-
tive studies [4,54–58], and 3 were case reports [59–61]. A total of
20 severe toxicity events in 75 patients were observed (27%)
(Fig. 3a): intratumoral haemorrhage (n = 11), headache (n = 2)
and cerebral oedema (n = 7). Overall, severe grade 3/4 cerebral
oedema was observed in 15% of patients (Table 2). The study of
Narayana et al. additionally described two deaths caused by cere-
bral oedema, but did not mention specifically whether this was
radiotherapy-related, nor whether these patients received concur-
rent treatment with WBRT or SRT [57]. None of the 10 SRT studies
reported severe skin toxicity, which is in contrast to experiences
from conventionally fractionated radiotherapy.
Two studies compared intratumoral haemorrhage after SRT
with concurrent BRAF-inhibitors to SRT alone [53,56]. Ly et al.
found an increased risk of haemorrhage (61% vs. 23%, no statistical
analysis) in their retrospective study of 17 patients, in which SRT
was performed with a median of 20 Gy in 1 fraction and BRAF-
inhibition was paused during SRT. In contrast, Wolf et al. showedTa
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Table 2
Toxicity as observed within the included articles.
Targeted therapy Study Patients
(n)
Grade 3 (n) Grade 4 (n) Grade 5 (n) Total
toxicity
(n)
Total toxicity
within the
irradiated
volume (n)
Bevacizumab 215 37 10 0 47 13
Cuneo et al. [20] 42 Radionecrosis, Fatigue, Headache, Changes in memory, Increase in seizure
activity, Worsening of neurological symptoms (n = 4) No significanant difference
to RT alone
NR NR 4 4
Gutin et al. [14] 25 Leukopenia (n = 2); Neutropenia (n = 2); Lymphopenia (n = 7);
Thrombocytopenia (n = 2); Anaemia (n = 3); Hyponatremia (n = 6); Fatigue
(n = 1); Hypertension (n = 1); CNS haemorrhage (n = 1)
Lymphopenia (n = 2);
Thrombocytopenia (n = 1);
Bowel perforation (n = 1);
Gastrointestinal bleeding
(n = 1); Wound-healing
disorder (n = 1)
NR 31 2
Wang et al. [16] 8 NR NR NR 0 0
Yomo et al. [23] 5 Anaemia (n = 1); Gastrointestinal bleeding (n = 1) NR NR 2 0
Minniti et al. [22] 26 Pulmonary embolism (n = 1); Wound dehiscence (n = 1) 2 1
Omuro et al. [15] 40 NR Renal failure (n = 1);
Pulmonary embolism
(n = 2); Surgical
woundinfection (n = 1)
NR 4 1
Cabrera et al. [13] 15 Headache (n = 1) NR NR 1 1
Clark et al. [18] 21 Seizure (n = 1); Dysphasia (n = 1) NR NR 2 2
Hasan et al. [21] 9 No Grade 2 or higher observed NR 0 0
Conde et al. [19] 9 No Grade 4 or higher observed
Cabrera et al.[24] 1 No toxicity observed NR 0 0
Barney et al. [17] 14 Gastric ulcer (n = 1) Gastric perforation (n = 1) NR 2 2
Trastuzumab 7 0 1 0 1 1
Carlson et al. [32] 7 NR Cerebral oedema (n = 1) NR 1 1
Cetuximab 244 31 0 1 32 32
Vargo et al. [28] 48 Mucositis (n = 1); Dermatitis (n = 1); Dysphagia (n = 2); Aerodigestive fistula
(n = 2)
NR NR 6 6
Lartigau et al. [27] 56 Dermatitis (n = 5); Mucositis (n = 4); Dysphagia (n = 3); Dysgeusia (n = 1); Skin
fibrosis (n = 1); Xerostomia (n = 1); Fistula (n = 1)
NR Haemorrhage/
denutrition (n = 1)
17 17
Vargo et al. [31] 72 PG3 acute toxicity significantly increased with addition of cetuximab (13% vs
10%, p = 0.008), no difference in late toxicity
Comet et al. [26] 15 Mucositis; Dysphagia; Induration/Fibrosis (n = 3) NR NR 3 3
Heron et al. [29] 35 Dysphagia (n = 2); Xerostomia (n = 2); Dysgeuisia (n = 1) NR NR 5 5
Quan et al. [30] 18 Mucositis (n = 1) NR NR 1 1
Ipilimumab 121 7 1 0 8 4
Kiess et al. [33] 15 Pruritus (n = 1); Hepatitis (n = 1); CNS haemorrhage (n = 2); Seizure (n = 2) Cardiopulmonary (n = 1) NR 7 4
Golden et al. [39] 1 NR NR NR 0 0
Tazi et al. [38] 10 Diarrhea (n = 1) NR NR 1 0
Silk et al. [37] 5 No increased toxicity compared to SRT alone (12.5% SRT vs. 3.9% SRT
+ ipilimumab, intratumoral haemorrhage, grading NR)
Mathew et al. [34] 25 NR NR NR 0 0
Hiniker et al. [40] 1 NR NR NR 0 0
Qin et al. [36] 44 No increased toxicity compared to ipilimumab alone (37 toxicities (ipilimumab)
vs. 33 toxicities (SRT + ipilimumab), unreported grading); pyrexia (n = 1); nausea
(n = 4); fatigue (n = 5); anorexia (n = 2); dermatologic (n = 12); GI (n = 8);
endocrine (n = 1)
Patel et al. [35] 20 Trend towards higher rates of radiation necrosis compared to SRT alone (30% vs.
21%, ns), no difference in haemorrhage, grading NR
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Table 2 (continued)
Targeted therapy Study Patients
(n)
Grade 3 (n) Grade 4 (n) Grade 5 (n) Total
toxicity
(n)
Total toxicity
within the
irradiated
volume (n)
Nivolumab 27 2 1 0 3 3
Alomari et al. [41] 1 NR Cerebral oedema (n = 1) NR 1 1
Ahmed et al. [42] 26 Cerebral oedema (n = 2) NR NR 2 2
Sorafenib/sunitinib 137 43 4 2 49 7
Staehler et al. [44] 106 Hypertension (4%); Rash (1%); Mucositis (1%); Diarrhea (1%); Thrombocytopenia
(2%); Anaemia (11%); Hand-foot-Syndrome (1%); Myocardial infarction (2%);
Thrombosis (1%)
NR Cerebral
haemorrhage (n = 1)
25 0
Brade et al. [45] 16 Thrombocytopenia (n = 4); Neutropenia (n = 1); Confusion (n = 1); Liver enzyme
changes (n = 2), Lower GI haemorrhage (n = 1)
Liver enzyme changes
(n = 1); Small bowel
obstruction (n = 1)
Upper GI
haemorrhage (n = 1)
12 6
Straka et al. [46] 1 NR NR NR 0 0
Ahluwalia et al.
[43]
14 Fatigue(n = 5); Neutropenia (n = 1); Haemolysis (n = 1); Stomatitis (n = 1);
Generalized muscle weakness (n = 1); Rash (n = 1)
Neutropenia (n = 1);
Lymphopenia (n = 1)
NR 12 1
Gefitinib/erlotinib 81 32 4 1 37 8
Wang et al. [51] 14 Skin acne (n = 1); Stomatitis (n = 1); Esophagitis (n = 1); Diarrhea (n = 1);
Radiation pneumonitis (n = 3); Fatigue (n = 1)
NR NR 8 4
Schwer et al. [49] 15 NR NR NR 0 0
Kim et al. [48] 18 NR NR NR 0 0
Iyengar et al. [47] 24 Total (n = 24); of which SRT related: Vertebral body compression (n = 1);
Radiation pneumonitis (n = 1)
Diarrhea (n = 1); Fatigue
(n = 1); Motor neuron
neuropathy (n = 1); SRT-
related: Hypoxia (n = 1)
Total (n = 13); of
which SRT related:
ARDS/pneumonia
(n = 1)
24 4
Weickhardt et al.
[50]
10 NR NR NR 0 0
Crizotinib 29 0 0 0 0 0
Gan et al. [52] 14 NR NR NR 0 0
Weickhardt et al.
[50]
15 NR NR NR 0 0
Vemurafenib/
dabrafenib
129 19 1 0 20 20
Ahmed et al. [54] 24 Haemorrhage (n = 1) NR NR 1 1
Peuvrel et al. [60] 1 Headache (n = 1) NR NR 1 1
Narayana et al.
[57]
6 No intracranial bleeding and noP Gr3 cutaneous toxicity observed
Ly et al. [56] 17 Increased haemorrhage risk associated with BRAF-inhibitors (61% vs 23%)
Liebner et al. [59] 2 Headache (n = 1) Cerebral oedema (n = 1) NR 2 2
Stefan et al. [61] 1 NR NR NR 0 0
Gaudy et al. [55] 24 Cerebral oedema (n = 6); Haemorrhage (n = 10) NR NR 16 16
Wolf et al. [53] 31 No significant difference in haemorrhage to RT alone (18% haemorrhage of
unreported grading for concurrent therapy)
Hecht et al. [4] 19 NR NR NR 0 0
Patel et al. [58] 4 No increased or unexpected neurologic nor cutaneous toxicity with
administration of SRS
Trametinib 4 0 0 0 0 0
Patel et al. [58] 4 No increased or unexpected neurologic nor cutaneous toxicity with
administration of SRS
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no significant difference in haemorrhage (16% after BRAF & SRT vs.
8% after SRT, ns), after performing SRT with 18G in 1 fraction. Both
studies did not report the severity of haemorrhage. While the stud-
ies of Ahmed et al. and Gaudy et al. observed grade 3 haemorrhage
in a total of 11 of 48 patients (23%) [55] [54], the remaining 6 stud-
ies did not observe intratumoral haemorrhage (Table 2).
In summary, data on CNS toxicity after combined cranial SRT
and BRAF-inhibitors is conflicting. However, high rates of toxicity
Fig. 2. Included studies and patients; X-axis: n = number of included studies. Size of the circle is proportional to the number of patients analysed (0, <100, P100).
Fig. 3. Cranial vs. extra-cranial severe toxicity evaluated per different targeted therapy class; (A) Cranial SRT; (B) Extra-cranial. Toxicity percentage is calculated as the
number of toxicity events per treated patients. The size of the circle represents the size of the patient population.
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reported in some studies warrant caution. There is no data on the
combination of BRAF inhibitors and extra-cranial SRT.
MEK-inhibitors (trametinib)
Currently, only Patel et al. evaluated the toxicity of concurrent
BRAF-, and MEK-inhibitor therapy with SRT [58]. This small retro-
spective study included only 4 patients with melanoma brain
metastasis that were treated with SRT and concurrent targeted
therapy. Median SRT dose was 21 Gy in 1 fraction and trametinib
was pasued 2–3 days before and after SRT, or it was initiated
within 1 month after SRT, with a median of 21 Gy in 1 fraction.
They did not observe any severe toxicity within a median follow-
up of 10.6 months.
In summary, the very small number of patients treated with
combined SRT and MEK inhibitors does not allow to draw any con-
clusions about its safety.
Discussion
This review shows that even though concurrent treatment with
SRT and targeted drugs or immunotherapy is increasingly per-
formed, available safety information is primarily based on small,
retrospective single institution experiences. Combined modality
treatment was most frequently studied in patients with brain
metastases or recurrent glioblastoma; substantially less data is
available for extra-cranial SRT.
In general, cranial SRT and concurrent targeted therapy is well
tolerated for the majority of evaluated targeted therapies. The best
safety data is available for SRT combined with bevacizumab, ipili-
mumab, nivolumab and EGFR-targeting TKIs. Bevacizumab may
possible even prevent SRT-induced radionecrosis [16]. Severe neu-
rotoxicity was mainly, but not consistently, reported when cranial
SRT was combined with BRAF-inhibitors (vemurafenib, dabrafe-
nib); it is unclear whether this variability reflects differences in
the practice of cranial SRT regarding radiotherapy dose, volume
and number of treated lesions or is simply the result of bias given
the retrospective nature of the studies. Interestingly, no severe skin
toxicity was observed, as known from the combination of vemu-
rafenib and conventionally fractionated radiotherapy. Severe toxi-
city observed after cranial SRT combined with bevacizumab,
sunitinib and sorafenib was primarily based on extra-cranial
events attributed to the systemic treatment, and not SRT.
Based on the more limited data of extra-cranial SRT concurrent
with targeted/immunotherapy, we found some indications of a
potentially increased risk of severe toxicity when extra-cranial
SRT was combined with bevacizumab, sorafenib, cetuximab and
EGFR-targeting TKIs. Interestingly, EGFR-targeting TKI-therapy
was well tolerated when combined with cranial SRT, but not with
extra-cranial SRT. For ALK- targeting crizotinib in patients with
metastatic NSCLC, no severe toxicity was observed in any study
of concurrent treatment with extra-cranial SRT. This emphasizes
that combination strategies of extra-cranial SRT are not universally
associated with increased risks but all combinations need to be
evaluated individually. However, for many targeted therapies
(e.g. pembrolizumab, alectinib, ceritinib, panitumumab, lapatinib),
so far no experiences of combined modality treatment have been
published.
Fig. 4. Total severe toxicity vs. toxicity within the irradiated volume evaluated per different targeted therapy class; (A) Totally observed toxicity; (B) SRT-attributed toxicity.
Toxicity percentage is calculated as the number of toxicity events per treated patients. The size of the circle represents the size of the patient population.
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This review has several limitations, which mainly reflects the
status of our current knowledge of concurrent treatments. We
focused on severe toxicity. In the search process, many studies
had to be excluded because toxicity was not clearly defined or
described. This is unfortunately a known problem in radiation
oncology research [62]. Furthermore, we observed that the avail-
able studies did not use a consistent definition of concurrent treat-
ment. We therefore chose to define concurrent therapy as targeted
therapy combined with SRT within one month of SRT. Studies that
shortly paused targeted therapy during SRT were included, as the
half-life of targeted therapy and especially immunotherapy is often
long (range 24 h – 50d) and several targeted therapies and
immunotherapies are administered once every 2 or 3 weeks, so that
treatment is concurrent even though not given at the same day.
In conclusion, cranial SRT was well tolerated when combined
with the majority of targeted drugs and immunotherapy but the
combination with BRAF-Inhibitors should be practiced with cau-
tion. Extra-cranial SRT was associated with higher risks when com-
bined with bevacizumab, sorafenib, cetuximab and EGFR-targeting
TKIs. However, this review also exposed multiple scenarios where
no data regarding safety is available. Nevertheless, it is expected
that concurrent SRT and targeted therapies will be increasingly
performed. As the design of homogeneous prospective trials exam-
ining safety is complicated by the rapidly growing number of avail-
able targeted agents and hugely divers combined treatment
strategies, a potential solution to generate better and quicker
knowledge could be the establishment of prospective registry
databases.
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